Collegium Pharmaceutical, Inc. (COLL) Stock Analysis
A live, multi-source view of Collegium Pharmaceutical, Inc. (COLL): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 423 employees · collegiumpharma.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Collegium Pharmaceutical, Inc. (COLL) had a market capitalization of $729.4M, a trailing P/E of 18.5 (forward 3.5) and a beta of 0.72; the shares traded in a 52-week range of $23.37 – $50.79 (-37.2% over the year).
- Market cap
- $729.4M
- Enterprise value
- $1.85B
- Trailing P/E
- 18.5
- Forward P/E
- 3.5
- Price / book
- 2.45
- EPS (trailing)
- $1.27
- EPS (forward)
- $6.77
- Payout ratio
- 0.0%
- 52-week range
- $23.37 – $50.79
- 52-week change
- -37.2%
- Beta
- 0.72
- Average volume
- 596,495
- Shares outstanding
- 31.0M
- Short % of float
- 23.94%
- Profit margin
- 5.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Collegium Pharmaceutical, Inc. (COLL) last closed at $23.53 (the last completed close before that scan).
Technicals at the scan: RSI 24 (oversold territory), price -11.1% versus its 20-day average, 20-day versus 50-day average spread -16.9%, MACD histogram -0.16.
Sentiment inputs: analyst consensus score 80/100.
Next scheduled company event: in 58 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for COLL in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
COLL has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Collegium Pharmaceutical, Inc. (COLL) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell COLL.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.